Tonghua Golden-Horse Pharmaceutical Industry000766.SZValuation Analysis

As of Oct 19, 2026, Tonghua Golden-Horse Pharmaceutical Industry (000766.SZ) trades at a P/E of 559.00x, P/B of 5.90x, P/S of 12.30x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 89th percentile over the trailing 10Y window (vs. 72nd percentile over 3Y); P/B sits at the 71st percentile over the trailing 10Y window (vs. 10th percentile over 3Y); P/S sits at the 72nd percentile over the trailing 10Y window (vs. 40th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 98th percentile within its industry and the 97th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 17.7 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Tonghua Golden-Horse Pharmaceutical Industry operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.